Skip to main content

Kane Biotech Inc(KNE-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.035
Day High0.035
Open:0.035
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
Newsfile
Upcoming Meeting Dates - April 20, 2026
GlobeNewswire
Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference
GlobeNewswire
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
GlobeNewswire
Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
GlobeNewswire
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
GlobeNewswire
Kane Biotech Expands Commercial Activities in the United States
GlobeNewswire
Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
GlobeNewswire
Kane Biotech Restarts Commercial Activities and Strengthens North American Management
INK Research
Off-market insider buying at Kane Biotech (KNE)
Company Chart of KNE
GlobeNewswire
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
GlobeNewswire
Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting
GlobeNewswire
Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
GlobeNewswire
Kane Biotech Announces Third Quarter 2025 Financial Results
GlobeNewswire
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
GlobeNewswire
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
GlobeNewswire
Kane Biotech Announces Second Quarter 2025 Financial Results
AI-generated - The Globe and Mail
Kane Biotech: Top 10 Undervalued Biotechnology Industry Stocks (KNE)
GlobeNewswire
Kane Biotech Provides Further Corporate Update
AI-generated - The Globe and Mail
Kane Biotech: Top 10 Undervalued Biotechnology Industry Stocks (KNE)
AI-generated - The Globe and Mail
Kane Biotech: Top 10 Undervalued Biotechnology Industry Stocks (KNE)
INK Research
Directors buying at Kane Biotech (KNE)
Company Chart of KNE
GlobeNewswire
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
AI-generated - The Globe and Mail
Kane Biotech: Top 10 Undervalued Biotechnology Industry Stocks (KNE)
GlobeNewswire
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
GlobeNewswire
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
AI-generated - The Globe and Mail
Kane Biotech: Top 10 Undervalued Biotechnology Industry Stocks (KNE)
GlobeNewswire
Kane Biotech Announces Second and Final Closing of Private Placement Offering
GlobeNewswire
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology
GlobeNewswire
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering
GlobeNewswire
Kane Biotech Announces $3,000,000 Private Placement Offering
GlobeNewswire
Kane Biotech Announces Third Quarter 2024 Financial Results

Profile

Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.